Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vasocedine is a combination pharmaceutical product primarily used as a nasal decongestant and antihistamine. It contains naphazoline, a sympathomimetic amine that acts as a potent vasoconstrictor by stimulating alpha-adrenergic receptors in the nasal mucosa, thereby reducing swelling and congestion. The second component, chlorphenamine, is a first-generation antihistamine that acts as a competitive antagonist at H1 histamine receptors, helping to alleviate allergic symptoms such as sneezing and rhinorrhea. The product is commonly marketed in Belgium by Qualiphar and has been the subject of formulation research at institutions like Ghent University (Universiteit Gent), particularly regarding nasal drug delivery systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphazoline + chlorphenamine.